Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age children
Authors:
- Osamu HiedaOHOsamu Hieda
- The ATOM-J Study GroupTGThe ATOM-J Study Group
- Yo NakamuraYNYo Nakamura
- Chie SotozonoCSChie Sotozono
- 7 August 2023
- journal article
- research article
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 67 (5) , 602-611
Abstract
Purpose Having previously demonstrated the efficacy of 0.01% atropine eye drops for inhibiting progression of childhood myopia, we conducted additional analyses to assess post-treatment changes in myopia progression. Study design Analysis of follow-up data from a previously reported randomized controlled trial Methods A mixed-effects model was used to compare intergroup changes in spherical equivalent (SE) and axial length (AL) at 1 month and 12 months after discontinuation of 2-year treatment with atropine or placebo in 167 school-age children. Results Follow-up measurements were available for 149 participants at 1 month after discontinuation of treatment and for 51 participants at 12 months after discontinuation. At 1 month post-treatment, differences between the atropine and placebo groups in least squares (LS) mean changes in SE and AL, respectively, from 24 months were −0.06 diopters (D) (95% CI: −0.21, 0.08; P = .39) and 0.02 mm (95% CI: −0.05, 0.08; P = .60). At 12 months post-treatment, intergroup differences (atropine vs placebo) in LS mean changes in SE and AL, respectively, were −0.13 D (95% CI: −0.35, 0.10; P = .26) and −0.02 mm (95% CI: −0.12, 0.09; P = .75). LS mean changes in SE and AL from treatment discontinuation did not differ between the groups at 1 or 12 months post-treatment. Conclusion Axial elongation was significantly less in the atropine group than in the placebo group. The suppression effect obtained at 2 years was maintained after 12 months. The absence of intergroup differences in myopia progression since treatment cessation suggests that myopic rebound did not occur.Keywords
Funding Information
- Eye-Lens Pte., Ltd.
This publication has 29 references indexed in Scilit:
- Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2Ophthalmology, 2016
- The effect of topical adrenergic and anticholinergic agents on the choroidal thickness of young healthy adultsExperimental Eye Research, 2014
- Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%American Journal of Ophthalmology, 2014
- Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide studyEye, 2013
- Long-Term Effect of Overnight Orthokeratology on Axial Length Elongation in Childhood Myopia: A 5-Year Follow-Up StudyInvestigative Ophthalmology & Visual Science, 2012
- Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)Ophthalmology, 2012
- Interventions to slow progression of myopia in childrenCochrane Database of Systematic Reviews, 2011
- Influence of Overnight Orthokeratology on Axial Elongation in Childhood MyopiaInvestigative Ophthalmology & Visual Science, 2011
- Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression after Cessation of AtropineOphthalmology, 2009
- Atropine for the Treatment of Childhood MyopiaOphthalmology, 2006